

Anti-GCGR Antibody (Crotedumab)

Introduction

Crotedumab (REGN1193) is a humanized IgG4 monoclonal antibody that binds to and inhibits the glucagon receptor (GCGR) with a KD of 0.1 nM. Crotedumab can be used in diabetes research.

Product parameters

Alternative Names	REGN1193
Target Accession	P47871
Target	GCGR
CAS number	1452387-69-7
Molecular Weight	146.82 kDa
Host	CHO
Reactivity	Human
Conjugation	Unconjugated
Form	Liquid
Concentration	See label
Buffer System	100 mM Pro 20 mM Arg pH 5.0. No preservative!
Clonality	Monoclonal
Purification	Protein A
Isotype	IgG4SP
Application	ELISA, FACS, Kinetics, Functional assay, Animal Model
Biological activity	Human GCCR His EGFP HEK293 cells were stained with Anti-GCGR Antibody (Crotedumab) and negative control protein respectively, washed and then followed by PE and analyzed with FACS, EC50=0.6028 ug/mL.
Endotoxin	Less than 0.1 EU/ug determined by LAL method.
Sterilization	0.2 µM filtered
Reconstitution	For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
Shipping	Dry ice
Storage	-80°C
Expiration Date	2 years
Note	Please avoid freeze-thaw cycles.

Note

1. This product is for scientific research use only.



APExBIO Technology

www.apexbt.com

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com

